Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Ono Pharmaceutical Co., Ltd.: Strengths and Weaknesses

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Ono Pharmaceutical Co., Ltd.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: Ono Pharmaceutical Co., Ltd.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Ono Pharmaceutical Co., Ltd. SectorJapan

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Ono Pharmaceutical Co., Ltd. SectorJapan

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Ono Pharmaceutical Co., Ltd. SectorJapan

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Ono Pharmaceutical Co., Ltd. SectorJapan

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Ono Pharmaceutical Co., Ltd. SectorJapan

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
7.18B
AA
47.36B
BB
34.11B
A
12.47B -
CCC
- - - - -
11.73B
A
10.11B
BB
8.76B
BB
-
8.16B -
6.84B
B
6.46B
A
Average 15.32B
BBB
Weighted average by Cap.
BBB
  1. Stock Market
  2. Equities
  3. 4528 Stock
  4. Ratings Ono Pharmaceutical Co., Ltd.
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW